Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 7
Submit an article Journal homepage
352
Views
41
CrossRef citations to date
0
Altmetric
Reviews

Optimizing gene delivery vectors for the treatment of heart disease

Steven J Gray University of North Carolina at Chapel Hill, Gene Therapy Center, Chapel Hill, North Carolina 27599, USA +1 919 962 3285; +1 919 966 0907; [email protected]
&
R Jude Samulski University of North Carolina at Chapel Hill, Gene Therapy Center, Chapel Hill, North Carolina 27599, USA +1 919 962 3285; +1 919 966 0907; [email protected]
Pages 911-922 | Published online: 12 Jun 2008

Bibliography

  • Damani SB, Topol EJ. Future use of genomics in coronary artery disease. J Am Coll Cardiol 2007;50(20):1933-40
  • Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep 2007;55(19):1-119
  • Pleis JR, Lethbridge-Cejku M. Summary health statistics for U.S. adults: National Health Interview Survey, 2005. Vital Health Stat 2006;(232):1-153
  • Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;117(4):e25-146. Published online 17 Dec 2007, doi:10.1161/CIRCULATIONAHA.107.187998
  • Available from: www.americanheart.org
  • Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171(4356):737-8
  • Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323(9):570-8
  • Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401(6753):517-8
  • Check E. Sanctions agreed over teenager's gene-therapy death. Nature 2005;433(7027):674
  • Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003;302(5644):415-9
  • Available from: http://www.wiley.co.uk/genetherapy/clinical
  • Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 2007;117(6):1456-65
  • Pike-Overzet K, van der Burg M, Wagemaker G, et al. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol Ther 2007;15(11):1910-6
  • Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007;15(7):1233-47
  • Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50(11):1038-46
  • Bhindi R, Fahmy RG, Lowe HC, et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol 2007;171(4):1079-88
  • Ly H, Kawase Y, Yoneyama R, Hajjar RJ. Gene therapy in the treatment of heart failure. Physiology (Bethesda) 2007;22:81-96
  • Muller OJ, Katus HA, Bekeredjian R. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 2007;73(3):453-62
  • Roques C, Salmon A, Fiszman MY, et al. Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm 2007;331(2):220-3
  • Lin H, Parmacek MS, Morle G, et al. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 1990;82(6):2217-21
  • Fromes Y, Salmon A, Wang X, et al. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 1999;6(4):683-8
  • Miyagawa S, Sawa Y, Taketani S, et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105(21):2556-61
  • Tokunaga N, Nagaya N, Shirai M, et al. Adrenomedullin gene transfer induces therapeutic angiogenesis in a rabbit model of chronic hind limb ischemia: benefits of a novel nonviral vector, gelatin. Circulation 2004;109(4):526-31
  • Lee M, Rentz J, Han SO, et al. Water-soluble lipopolymer as an efficient carrier for gene delivery to myocardium. Gene Ther 2003;10(7):585-93
  • Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007;24(3):438-49
  • Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007;7(3):189-204
  • Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004;6(Suppl 1):S164-71
  • Wright MJ, Wightman LM, Lilley C, et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001;96(3):227-36
  • Schiedner G, Morral N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18(2):180-3
  • Chen HH, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997;94(5):1645-50
  • McConnell MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15(11):1022-33
  • Amalfitano A. Next-generation adenoviral vectors: new and improved. Gene Ther 1999;6(10):1643-5
  • Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15(12):1157-66
  • Vilquin JT, Guerette B, Kinoshita I, et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995;6(11):1391-401
  • Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005;12(7):579-87
  • Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001;8(5):341-8
  • Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005;11(1):66-79
  • Romanczuk H, Galer CE, Zabner J, et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther 1999;10(16):2615-26
  • Menezes KM, Mok HS, Barry MA. Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors. Hum Gene Ther 2006;17(3):314-20
  • Nakayama M, Both GW, Banizs B, et al. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 2006;350(1):103-15
  • Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J Virol 2005;79(18):11627-37
  • Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol 2002;76(9):4612-20
  • Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006;1(3):1412-28
  • Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006;99(4):e3-9
  • Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14(1):45-53
  • Palomeque J, Chemaly ER, Colosi P, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther 2007;14(13):989-97
  • Lyon AR, Sato M, Hajjar RJ, et al. Gene therapy: targeting the myocardium. Heart 2008;94(1):89-99
  • Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007;5(1):16-24
  • Choi VW, McCarty DM, Samulski RJ. Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol 2006;80(21):10346-56
  • Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006;14(3):452-5
  • Di Pasquale G, Chiorini JA. AAV transcytosis through barrier epithelia and endothelium. Mol Ther 2006;13(3):506-16
  • Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005;79(15):9933-44
  • Halbert CL, Allen JM, Miller AD. Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene. Nat Biotechnol 2002;20(7):697-701
  • Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther 2008;16(1):124-30
  • Grieger JC, Samulski RJ. Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications. Adv Biochem Eng Biotechnol 2005;99:119-45
  • Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr Gene Ther 2007;7(5):325-33
  • Halbert CL, Miller AD, McNamara S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17(4):440-7
  • Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999;73(5):3994-4003
  • Hildinger M, Auricchio A, Gao G, et al. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001;75(13):6199-203
  • Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
  • Le HT, Yu QC, Wilson JM, Croyle MA. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. J Control Release 2005;108(1):161-77
  • Chu D, Sullivan CC, Weitzman MD, et al. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. J Thorac Cardiovasc Surg 2003;126(3):671-9
  • McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10(26):2112-8
  • Su H, Huang Y, Takagawa J, et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006;13(21):1495-502
  • Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005;16(5):541-50
  • Raake PW, Hinkel R, Muller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 2008;15(1):12-7
  • Kaspar BK, Roth DM, Lai NC, et al. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med 2005;7(3):316-24
  • Pleger ST, Most P, Boucher M, et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007;115(19):2506-15
  • Jacquier A, Higgins CB, Martin AJ, et al. Injection of adeno-associated viral vector encoding vascular endothelial growth factor gene in infarcted swine myocardium: MR measurements of left ventricular function and strain. Radiology 2007;245(1):196-205
  • Liu X, Simpson JA, Brunt KR, et al. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol 2007;293(1):H48-59
  • Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007;36(3):184-204
  • Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998;72(10):8150-7
  • Bahner I, Sumiyoshi T, Kagoda M, et al. Lentiviral vector transduction of a dominant-negative rev gene into human CD34(+) hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol Ther 2007;15(1):76-85
  • Sattentau QJ, Weiss RA. The CD4 antigen: physiological ligand and HIV receptor. Cell 1988;52(5):631-3
  • Bonci D, Cittadini A, Latronico MV, et al. ‘Advanced’ generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 2003;10(8):630-6
  • Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003;101(6):2099-114
  • Baum C, von Kalle C. Gene therapy targeting hematopoietic cells: better not leave it to chance. Acta Haematol 2003;110(2-3):107-9
  • Philpott NJ, Thrasher AJ. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007;186:483-489
  • Zhu K, Dobard C, Chow SA. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase. J Virol 2004;78(10):5045-55
  • Gallay P, Hope T, Chin D, Trono D. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci USA 1997;94(18):9825-30
  • Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006;12(3):348-53
  • Yoshimitsu M, Higuchi K, Dawood F, et al. Correction of cardiac abnormalities in fabry mice by direct intraventricular injection of a recombinant lentiviral vector that engineers expression of α-galactosidase A. Circ J 2006;70(11):1503-8
  • Beck C, Uramoto H, Boren J, Akyurek LM. Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther 2004;4(4):457-67
  • Franz WM, Rothmann T, Frey N, Katus HA. Analysis of tissue-specific gene delivery by recombinant adenoviruses containing cardiac-specific promoters. Cardiovasc Res 1997;35(3):560-6
  • LaPointe MC, Yang XP, Carretero OA, He Q. Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector. Am J Physiol Heart Circ Physiol 2002;283(4):H1439-45
  • Franz WM, Breves D, Klingel K, et al. Heart-specific targeting of firefly luciferase by the myosin light chain-2 promoter and developmental regulation in transgenic mice. Circ Res 1993;73(4):629-38
  • Gruh I, Wunderlich S, Winkler M, et al. Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. J Gene Med 2008;10(1):21-32
  • Muller OJ, Leuchs B, Pleger ST, et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 2006;70(1):70-8
  • Pachori AS, Melo LG, Hart ML, et al. Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci USA 2004;101(33):12282-7
  • Su H, Joho S, Huang Y, et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 2004;101(46):16280-5
  • Okada Y, Yano K, Jin E, et al. A three-kilobase fragment of the human Robo4 promoter directs cell type-specific expression in endothelium. Circ Res 2007;100(12):1712-22
  • Greenberger S, Shaish A, Varda-Bloom N, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004;113(7):1017-24
  • Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19(9):838-42
  • Rutanen J, Rissanen TT, Markkanen JE, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004;109(8):1029-35
  • Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004;10(8):828-34
  • Sasano T, Kikuchi K, McDonald AD, et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol 2007;42(5):954-61
  • Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006;113(11):1451-63
  • Tao ZW, Li LG. Cell therapy in congestive heart failure. J Zhejiang Univ Sci B 2007;8(9):647-60
  • Bearzi C, Rota M, Hosoda T, et al. Human cardiac stem cells. Proc Natl Acad Sci USA 2007;104(35):14068-73
  • Ye L, Haider H, Sim EK. Adult stem cells for cardiac repair: a choice between skeletal myoblasts and bone marrow stem cells. Exp Biol Med (Maywood) 2006;231(1):8-19
  • Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy. Eur J Heart Fail 2008;10(1):102-8
  • van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117(9):2369-76
  • Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007;101(12):1225-36
  • Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9(2):102-14
  • Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37(5):495-500
  • Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31(3):367-73
  • van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007;316(5824):575-9
  • Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13(5):613-8
  • Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007;170(6):1831-40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.